转自：贵州日报 1月23日至24日，2025第八届品牌强国经济论坛暨创新成果推介活动上，贵州铭肽生物科技有限公司 （Utide）凭借在多肽药物研发与产业化领域的突出贡献，一举摘得"2025品牌强国·多肽药物产业新质生 产力标杆企业""2025品牌强国·大健康多肽药物最佳技术创新成果案例"两项重磅荣誉。该公司总经理王 仁友同步入选"2025品牌强国·大健康多肽药物产业十大领军人物"，成为行业创新发展的标杆。 据了解，贵州铭肽生物科技有限公司位于遵义市红花岗区医药健康产业园，是一家专注于多肽原料研 发、生产与销售的高新技术企业。公司凭借在GLP-1系列多肽原料领域的核心工艺技术，迅速成长为全 球相关药物供应链中的重要一环，产品远销北美、欧洲、东南亚等国际市场。 贵州铭肽生物科技有限公司相关负责人表示，将始终聚焦多肽原料核心技术突破，通过产学研深度融 合，在提升药物疗效、降低生产成本等方面不断突破，为推动行业高质量发展注入"贵州力量"。 （刘振梁） 本次评选由中国商报社、《中国商界》杂志社等单位联合主办，依据《中国品牌影响力评价通则》 （T/CCPITCSC 120-2023）及第三方权威评估，旨在表彰推动产业升级 ...

Core Viewpoint - Shengnuo Biopharma (688117.SH) is experiencing explosive growth in its performance, with a projected net profit of 152 million to 190 million yuan for 2025, representing a year-on-year increase of 204.42% to 280.53% [1][2] Financial Performance - Shengnuo Biopharma's revenue for 2022 was 396 million yuan, with a net profit of 64.48 million yuan. In 2023, revenue increased to 435 million yuan and net profit to 70.34 million yuan. In 2024, revenue reached 456 million yuan, while net profit slightly declined to 50.02 million yuan, setting the stage for the anticipated growth in 2025 [2] - For 2025, the company expects a significant leap in performance, with net profit projected between 152 million and 190 million yuan, and a non-recurring net profit forecasted between 149 million and 186 million yuan, indicating substantial growth compared to previous years [2] Business Growth Drivers - The core drivers of Shengnuo Biopharma's explosive growth include the rapid expansion of its peptide raw material business and simultaneous market development both domestically and internationally [2] - The company has successfully established a complete industrial chain platform covering peptide raw materials, formulation products, and innovative drug CDMO services over its 20 years of operation [2] Revenue Structure - Shengnuo Biopharma's revenue structure is primarily driven by raw materials and intermediates, with raw materials accounting for 56% of total revenue in the first half of 2025, showing a significant year-on-year growth of 232% [3] - The demand for GLP-1 raw materials has surged globally, driven by the penetration of original drug products in diabetes and obesity treatment, allowing Shengnuo to capitalize on this industry trend [3] Research and Development - The company has steadily increased its R&D investment over the years, with total R&D expenditure reaching 149 million yuan over the past five years, indicating a commitment to enhancing its core technologies and product pipeline [4] - Shengnuo Biopharma has provided peptide innovation drug research and custom production services to over 40 new drug development companies, with several projects at critical clinical trial stages [5] Asset Growth - Shengnuo Biopharma's total assets reached 19.09 billion yuan by the end of the third quarter of 2025, marking a 24.93% year-on-year increase and surpassing the 19 billion yuan milestone [5]

Core Viewpoint - Shengnuo Biotech is expected to achieve significant growth in its peptide API business, driven by capacity expansion and increasing market demand, enhancing its global competitiveness in the peptide pharmaceutical market [1][2][3] Company Performance - Shengnuo Biotech forecasts a net profit attributable to shareholders of approximately 152 million to 190 million yuan for 2025, representing a year-on-year increase of about 102 million to 140 million yuan, or a growth rate of 204.42% to 280.53% [3] - The company's net profit, excluding non-recurring gains and losses, is expected to be around 149 million to 186 million yuan, reflecting a year-on-year increase of approximately 103 million to 140 million yuan, or a growth rate of 226.07% to 307.58% [3] Market Dynamics - Shengnuo Biotech's API products are sold in regions including Europe, the United States, and South Korea, establishing partnerships with well-known pharmaceutical companies such as Fresenius Kabi and others [2] - The global demand for GLP-1 (glucagon-like peptide-1) drugs is high, significantly driving the company's performance [2] - The global peptide drug market is projected to reach 210.8 billion USD by 2030, indicating a strong growth trajectory for the industry [2] Operational Strategy - Shengnuo Biotech is focused on expanding its production capacity while exploring domestic and international markets, which is expected to lead to a steady increase in overall performance [1] - The company has successfully launched several key projects, including a peptide API production line with an annual capacity of 395 kilograms and a formulation industrialization project [1] - The company has developed a differentiated capability through its GMP production capacity system, which helps mitigate risks associated with reliance on single customers [4]

Core Insights - The peptide drug sector is rapidly growing, with a projected global market size of $210.8 billion by 2030, driven by high activity, low toxicity, and strong targeting capabilities [1] - The company Hanyu Pharmaceutical has implemented a dual CEO management model to enhance collaboration and efficiency in drug development and market conversion [2][3] Industry Trends - The peptide drug industry, particularly in the GLP-1 segment, is experiencing a golden growth period with increasing competition [4] - Companies are focusing on differentiating their products through innovative drug design and effective market strategies to avoid homogenization [4][5] Company Strategy - Hanyu Pharmaceutical aims to build a competitive edge through a comprehensive industry chain, innovative research and development, and international quality standards [5] - The company has established a differentiated advantage in the GLP-1 pipeline by offering various dosage forms and maintaining low production costs [5] Future Outlook - Hanyu Pharmaceutical plans to leverage three strategic cards: enhancing international sales, preemptively positioning for expiring patents, and extending into innovative drug and technology platforms [7][8] - The company is focusing on long-term growth by addressing unmet clinical needs and exploring the small nucleic acid drug sector, which is expected to be a key growth area in the next 1 to 3 years [8]

Group 1 - The company achieved revenue of 270 million yuan in the first half of 2025, representing a year-on-year growth of 20.10%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.31% year-on-year [1] - In Q2 2025, the company reported revenue of 135 million yuan, a year-on-year increase of 0.94%, with a net profit of 41.09 million yuan, growing 14.19% year-on-year [1] - The demand for peptide drugs, particularly GLP-1 drugs like semaglutide and tirzepatide, is rapidly increasing, contributing to the company's performance [1] Group 2 - The company has established long-term stable partnerships with over 1,900 pharmaceutical R&D and production enterprises globally, including major players like Bachem AG and Lonza AG [2] - A wholly-owned subsidiary, Highfine Biotech GmbH, was established in Germany in January 2025 to enhance connections and services for European clients [2] - The company is expanding its production capacity through self-built facilities and acquisitions, with significant projects underway to alleviate supply bottlenecks [2]

Core Viewpoint - Notai Bio (688076.SH) has been penalized for financial fraud, leading to a downgrade in valuation by fund companies after being designated as ST (Special Treatment) following its resumption of trading [2][7]. Group 1: Financial Fraud and Penalties - The China Securities Regulatory Commission (CSRC) confirmed that Notai Bio's 2021 annual report contained false records, resulting in a total fine of 76.2 million yuan for the company and several executives [2][6]. - Notai Bio's fraudulent activities included inflating revenue by 30 million yuan and profit by 25.95 million yuan, which accounted for 20.64% of the reported total profit for that year [4][5]. - The company was also penalized for providing misleading financial information in its bond issuance documents, leading to additional fines totaling 47.4 million yuan [5][6]. Group 2: Market Impact and Fund Valuation Adjustments - Following the ST designation, Notai Bio's stock closed at 44.51 yuan per share, with a total market capitalization of 14.07 billion yuan [3]. - On July 22, 2025, the valuation of Notai Bio's stock was adjusted to 32.78 yuan by the招商基金, reflecting a reduction of approximately 20% from its previous price of 40.98 yuan [8][9]. - As of the end of Q2 2025, 19 funds from 8 public fund companies held a total of 9.23 million shares of Notai Bio, with a combined market value of 344 million yuan, representing 2.93% of the total share capital [10].

Core Insights - The "Flying Economy" model is driving the deep integration of the Yangtze River Delta region through the cooperation of Shanghai and Jiangsu in industrial parks [1][2] Group 1: Industrial Development - The Shanghai-Jiangsu cooperative industrial park, known as the "Dafeng Industrial Linkage Gathering Area," has developed 4 square kilometers and is strategically located between Dafeng urban area and the port, enhancing connectivity [1] - The gathering area focuses on three main industries: new energy, new infrastructure, and new agriculture, achieving over 10 billion yuan in sales in both 2023 and 2024, ranking third in total sales within Dafeng District [1] - Tax revenue from the gathering area exceeded 100 million yuan for two consecutive years, reaching 131 million yuan in 2024, a year-on-year increase of 24.8% [1] Group 2: Major Projects - The Zhengtai New Energy base, a significant project in the area, has a total investment of 3 billion yuan and is part of a collaborative effort among Jiangsu, Zhejiang, and Shanghai [2] - The base is projected to achieve an output value of 6.2 billion yuan and sales of 9.2 billion yuan in 2024, with a tax contribution of 95 million yuan [2] - The overall operating rate of the base is approximately 80%, with the Salt City base reaching 91% [2] Group 3: Infrastructure and Planning - The operational core of the gathering area is based on mutual connectivity between Shanghai and Jiangsu, requiring top-level planning, infrastructure development, project leadership, and technological innovation [2][3] - Collaborative efforts include over 20 specialized fields such as industry, transportation, and public welfare, guided by documents like the "Dafeng District Land Spatial Division Planning" [2] - Infrastructure development is being coordinated through investment platforms at the municipal and district levels to enhance supporting facilities [2] Group 4: Innovation and Collaboration - The cooperation between Shanghai and Jiangsu has led to the establishment of research institutes, such as the Jiangsu Coastal Low-Carbon Industry Technology Research Institute and the Qingdao University Marine Wind Power Research Institute [3] - The Nantong North High-tech Zone, a collaborative project between Jiangsu and Shanghai, has achieved a GDP output of 29 billion yuan in 2024, focusing on strategic emerging industries like automotive electronics and integrated circuits [4] - Approximately 40% of the over 300 technology-driven enterprises in the high-tech zone originate from Shanghai, with significant collaboration with Shanghai's universities and research institutions [4]